Published in:
01-10-2013 | Clinical and Epidemiological Study
Factors influencing liver fibrosis and necroinflammation in HIV/HCV coinfection and HCV monoinfection
Authors:
C. Sagnelli, C. Uberti-Foppa, G. Pasquale, S. De Pascalis, N. Coppola, L. Albarello, C. Doglioni, A. Lazzarin, E. Sagnelli
Published in:
Infection
|
Issue 5/2013
Login to get access
Abstract
Objectives
To define differences in liver histology between HIV/HCV coinfection and HCV monoinfection, and to investigate possible causative factors.
Methods
Liver biopsies (LBs) from 440 consecutive HIV/HCV-coinfected patients (Group HIV/HCV) and 374 consecutive HCV-monoinfected patients (Group HCV) were evaluated for necroinflammation and fibrosis (Ishak) by a pathologist unaware of the clinical and laboratory data. All patients were HBsAg-negative, with no history of alcohol abuse and naïve to anti-HCV treatment. At LB, 78.4 % of patients in Group HIV/HCV were on an antiretroviral regimen.
Results
HIV/HCV-coinfected patients compared to the HCV-monoinfected patients were younger (p < 0.0001), more frequently males (p < 0.0001), and had HCV genotype 3 (p < 0.0001); they showed a good immunological condition (CD4+ cell count: 518 ± 166 cells/mm3). Patients in Group HIV/HCV more frequently showed a fibrosis score ≥4 (27.5 vs. 20.6 %, p < 0.05) and a necroinflammation score ≥9 (25.9 vs. 13.4 %; p < 0.0001). The prevalence of patients with fibrosis score ≥4 was significantly higher in older age classes in both Group HIV/HCV (p < 0.005) and Group HCV (p < 0.05). A necroinflammation score ≥9 was significantly higher in older age classes only in Group HIV/HCV (p < 0.05). A multivariate analysis for Group HIV/HCV revealed that the patient age and nadir of CD4+ cell count were independently associated to higher degrees of fibrosis, the patient age and antiretroviral treatment were associated to higher degrees of necroinflammation, and HCV genotype 3 was associated to higher degrees of steatosis.
Conclusion
The data suggest a need for early anti-HCV treatment in both HCV-monoinfected and HIV/HCV-coinfected patients.